LigaChem Biosciences enters license agreement with GO Therapeutics

CAR-T Digest - August 2020

09 September 2025: LigaChem Biosciences enters license agreement with GO Therapeutics

LigaChem Biosciences signed a licensing agreement with U.S. based GO Therapeutics to develop and commercialize ADCs using GO’s antibody
The licensed antibody targets tumor-specific antigens expressed only on cancer cells, aiming to overcome on-target toxicity common in existing solid tumor therapies
LigaChemBio plans to create ADCs addressing high unmet needs in lung, breast, ovarian and colorectal cancers
This is LigaChemBio’s fifth oncology antibody license in 2025 as part of its strategy to build a strong, globally licensable ADC pipeline with innovative payloads
The collaboration combines GO Therapeutics’ novel targeting approach with LigaChemBio’s ADC expertise under its VISION 2030 plan to generate multiple new ADC candidates and advance them rapidly into clinical trials